NeuroMetrix (NASDAQ:NURO) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Sunday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

NeuroMetrix stock opened at $3.90 on Friday. The company has a market cap of $7.97 million, a P/E ratio of -0.85 and a beta of 2.18. NeuroMetrix has a one year low of $2.66 and a one year high of $4.73. The business has a fifty day moving average of $4.06 and a two-hundred day moving average of $3.84.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. The company had revenue of $0.59 million during the quarter. During the same period last year, the business earned ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.